MA38080A1 - Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 - Google Patents
Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1Info
- Publication number
- MA38080A1 MA38080A1 MA38080A MA38080A MA38080A1 MA 38080 A1 MA38080 A1 MA 38080A1 MA 38080 A MA38080 A MA 38080A MA 38080 A MA38080 A MA 38080A MA 38080 A1 MA38080 A1 MA 38080A1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutically acceptable
- adp
- ribose
- polymerase
- poly
- Prior art date
Links
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 title 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
La présente invention concerne des nouveaux composés de formule générale (i), leurs stéréoisomères, leurs régioisomères, leurs formes tautomères et des nouveaux intermédiaires impliqués dans leur synthèse, leurs sels pharmaceutiquement acceptables, leurs solvates pharmaceutiquement acceptables et des compositions pharmaceutiques les contenant. La présente invention concerne également un procédé de préparation des nouveaux composés de formule générale (i), de leurs stéréoisomères, de leurs régioisomères, de leurs formes tautomères, de leurs sels pharmaceutiquement acceptables, de leurs solvates pharmaceutiquement acceptables, de compositions pharmaceutiques les contenant et de nouveaux intermédiaires impliqués dans leur synthèse. Les composés de formule (i) sont utiles comme inhibiteurs de parp-1 pour le traitement, par exemple, du cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3742MU2012 | 2012-12-31 | ||
| PCT/IN2013/000794 WO2014102817A1 (fr) | 2012-12-31 | 2013-12-23 | Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38080A1 true MA38080A1 (fr) | 2018-02-28 |
Family
ID=54198806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38080A MA38080A1 (fr) | 2012-12-31 | 2013-12-23 | Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9598418B2 (fr) |
| EP (1) | EP2938598B1 (fr) |
| JP (1) | JP5930452B2 (fr) |
| KR (1) | KR101652654B1 (fr) |
| CN (1) | CN104918917A (fr) |
| AP (1) | AP2015008439A0 (fr) |
| AR (1) | AR094299A1 (fr) |
| AU (1) | AU2013368842B2 (fr) |
| BR (1) | BR112015012425A2 (fr) |
| CA (1) | CA2890309A1 (fr) |
| CL (1) | CL2015001655A1 (fr) |
| CO (1) | CO7400872A2 (fr) |
| DK (1) | DK2938598T3 (fr) |
| EA (1) | EA201591239A1 (fr) |
| ES (1) | ES2614885T3 (fr) |
| GE (1) | GEP201706691B (fr) |
| HR (1) | HRP20170219T1 (fr) |
| HU (1) | HUE030613T2 (fr) |
| IL (1) | IL238714A0 (fr) |
| MA (1) | MA38080A1 (fr) |
| MX (1) | MX2015006780A (fr) |
| NZ (1) | NZ708255A (fr) |
| PH (1) | PH12015501199B1 (fr) |
| PL (1) | PL2938598T3 (fr) |
| PT (1) | PT2938598T (fr) |
| SG (1) | SG11201503670YA (fr) |
| TW (1) | TWI553005B (fr) |
| WO (1) | WO2014102817A1 (fr) |
| ZA (1) | ZA201503218B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| DK3074400T3 (en) | 2013-11-26 | 2018-01-15 | Hoffmann La Roche | Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors |
| CA2937616A1 (fr) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Composes bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa) |
| EP3298005B1 (fr) | 2015-05-21 | 2024-01-24 | The Regents of The University of California | Composés anti-cancereux |
| CA2992889A1 (fr) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Derives de phenoxymethyle |
| JP6876685B2 (ja) * | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| AU2016328436B2 (en) * | 2015-09-24 | 2020-05-14 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| BR112017026682A2 (pt) | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| WO2017050732A1 (fr) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| WO2017071636A1 (fr) * | 2015-10-30 | 2017-05-04 | 四川科伦博泰生物医药股份有限公司 | Dérivé de phthalazine cétone, son procédé de préparation et son utilisation |
| WO2017101796A1 (fr) * | 2015-12-16 | 2017-06-22 | 四川科伦博泰生物医药股份有限公司 | Dérivé de phtalazinone, et procédé de préparation et utilisation associés |
| WO2017223516A1 (fr) * | 2016-06-24 | 2017-12-28 | The Regents Of The University Of California | Dérivés de phtalazine utiles en tant qu'inhibiteurs de parp1, parp2 et/ou de tubuline dans le traitement du cancer |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| CN109251204A (zh) * | 2017-07-13 | 2019-01-22 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| CN108164468B (zh) * | 2018-02-09 | 2021-02-02 | 上海卫岑医药科技有限公司 | 一种parp抑制剂、其药物组合物、制备方法及应用 |
| EP3852791B1 (fr) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activation de la pyruvate kinase r |
| EP3853206B1 (fr) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Traitement de la drépanocytose avec un composé activant la pyruvate kinase r |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| WO2021225407A1 (fr) * | 2020-05-08 | 2021-11-11 | 주식회사 티씨노바이오사이언스 | Nouveau dérivé de phtalazine ayant une activité d'inhibition de l'ectonucléotide pyrophosphatase/phosphodiestérase, et son utilisation |
| US20240208912A1 (en) * | 2021-03-11 | 2024-06-27 | Mirati Therapeutics, Inc. | MTA-Cooperative PRMT5 Inhibitors |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| US20240317762A1 (en) * | 2021-07-16 | 2024-09-26 | Oregon Health & Science University | Phthalazinone-based parp-1 inhibitors |
| JP2025509404A (ja) * | 2022-03-15 | 2025-04-11 | ベイジーン スイッツァランド ゲーエムベーハー | Ｐｒｍｔ５のｍｔａ協働阻害剤としての４－（アミノメチル）－６－（１－メチル－１ｈ－ピラゾール－４－イル）イソキノリン－１（２ｈ）－オン誘導体 |
| WO2024046420A1 (fr) * | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | Composé bicyclique fusionné, son procédé de préparation et son utilisation en médecine |
| CN116874496B (zh) * | 2023-07-10 | 2025-07-25 | 东南大学 | 三环类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| ATE501138T1 (de) | 2004-01-05 | 2011-03-15 | Astrazeneca Ab | Thiophenderivate als chk-1-inhibitoren |
| JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
| US20060079510A1 (en) | 2004-09-30 | 2006-04-13 | Kristoffer Hellstrand | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
| EP1869052A1 (fr) | 2005-04-06 | 2007-12-26 | AstraZeneca AB | Heterocycles substitues et leur utilisation en tant qu inhibiteurs de la chk1, de la pdk1 et de la pak |
| ES2361566T3 (es) | 2005-11-25 | 2011-06-20 | Pharma Mar S.A., Sociedad Unipersonal | Uso de inhibidores de parp-1. |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| ES2548353T3 (es) * | 2006-12-28 | 2015-10-15 | Abbvie Inc. | Inhibidores de poli(ADP-ribosa)polimerasa |
| US20100249112A1 (en) | 2007-05-25 | 2010-09-30 | Astrazeneca R&D | Combination of chk and parp inhibitors for the treatment of cancers |
| US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| EP2220073B1 (fr) * | 2007-11-15 | 2014-09-03 | MSD Italia S.r.l. | Derivés de pyridazinone inhibiteurs de la parp |
| UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| CA2737400C (fr) | 2008-10-07 | 2016-11-22 | Astrazeneca Uk Limited | Formulation pharmaceutique |
| JP2013532683A (ja) | 2010-07-27 | 2013-08-19 | カディラ ヘルスケア リミティド | ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体 |
| CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372698A (zh) * | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| JP5699223B2 (ja) * | 2010-12-02 | 2015-04-08 | シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド | 複素環誘導体、その合成法および医療用途 |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| TWI577693B (zh) | 2011-05-31 | 2017-04-11 | 江蘇康緣藥業股份有限公司 | 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 |
| ES2562903T3 (es) | 2011-07-13 | 2016-03-09 | Santen Pharmaceutical Co., Ltd | Nuevo compuesto que tiene actividad inhibidora de PARP |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| MX2014008071A (es) | 2011-12-31 | 2015-07-06 | Beigene Ltd | Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas. |
| CN103242273B (zh) | 2012-02-09 | 2015-06-03 | 中国科学院上海药物研究所 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
| UA116627C2 (uk) | 2012-02-09 | 2018-04-25 | Мерк Патент Гмбх | Похідні тетрагідрохіназоліну як інгібітори tank та parp |
-
2013
- 2013-12-23 HU HUE13828996A patent/HUE030613T2/en unknown
- 2013-12-23 DK DK13828996.2T patent/DK2938598T3/en active
- 2013-12-23 SG SG11201503670YA patent/SG11201503670YA/en unknown
- 2013-12-23 AU AU2013368842A patent/AU2013368842B2/en not_active Ceased
- 2013-12-23 JP JP2015550210A patent/JP5930452B2/ja not_active Expired - Fee Related
- 2013-12-23 US US14/647,088 patent/US9598418B2/en not_active Expired - Fee Related
- 2013-12-23 PL PL13828996T patent/PL2938598T3/pl unknown
- 2013-12-23 AP AP2015008439A patent/AP2015008439A0/xx unknown
- 2013-12-23 MA MA38080A patent/MA38080A1/fr unknown
- 2013-12-23 PT PT138289962T patent/PT2938598T/pt unknown
- 2013-12-23 KR KR1020157017355A patent/KR101652654B1/ko not_active Expired - Fee Related
- 2013-12-23 CN CN201380069025.0A patent/CN104918917A/zh active Pending
- 2013-12-23 WO PCT/IN2013/000794 patent/WO2014102817A1/fr not_active Ceased
- 2013-12-23 BR BR112015012425A patent/BR112015012425A2/pt not_active IP Right Cessation
- 2013-12-23 NZ NZ708255A patent/NZ708255A/en not_active IP Right Cessation
- 2013-12-23 GE GEAP201313901A patent/GEP201706691B/en unknown
- 2013-12-23 EA EA201591239A patent/EA201591239A1/ru unknown
- 2013-12-23 CA CA2890309A patent/CA2890309A1/fr not_active Abandoned
- 2013-12-23 EP EP13828996.2A patent/EP2938598B1/fr not_active Not-in-force
- 2013-12-23 ES ES13828996.2T patent/ES2614885T3/es active Active
- 2013-12-23 MX MX2015006780A patent/MX2015006780A/es unknown
- 2013-12-26 TW TW102148473A patent/TWI553005B/zh not_active IP Right Cessation
- 2013-12-27 AR ARP130105054A patent/AR094299A1/es unknown
-
2015
- 2015-05-08 ZA ZA2015/03218A patent/ZA201503218B/en unknown
- 2015-05-10 IL IL238714A patent/IL238714A0/en not_active IP Right Cessation
- 2015-05-28 PH PH12015501199A patent/PH12015501199B1/en unknown
- 2015-06-03 CO CO15127891A patent/CO7400872A2/es unknown
- 2015-06-12 CL CL2015001655A patent/CL2015001655A1/es unknown
-
2017
- 2017-02-09 HR HRP20170219TT patent/HRP20170219T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38080A1 (fr) | Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 | |
| MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| TN2014000033A1 (fr) | Indazoles | |
| MY155653A (en) | Triazine compounds as p13 kinase and mtor inhibitors | |
| MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA32351B1 (fr) | Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer | |
| MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA27801A1 (fr) | Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
| MX2008013583A (es) | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. | |
| MA31710B1 (fr) | (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament | |
| MX2011012337A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades. | |
| NZ612909A (en) | Processes for preparing isoquinolinones and solid forms of isoquinolinones | |
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) |